JP2008508320A - Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物 - Google Patents

Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物 Download PDF

Info

Publication number
JP2008508320A
JP2008508320A JP2007523880A JP2007523880A JP2008508320A JP 2008508320 A JP2008508320 A JP 2008508320A JP 2007523880 A JP2007523880 A JP 2007523880A JP 2007523880 A JP2007523880 A JP 2007523880A JP 2008508320 A JP2008508320 A JP 2008508320A
Authority
JP
Japan
Prior art keywords
gbs
gas
protein
pneumoniae
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007523880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508320A5 (https=
Inventor
ジョン エル． テルフォード，
ギド グランディ，
ピーター ラウア，
マリロサ モラ，
イマキュラダ マルガリート ワイ． ロス，
ドミニコ マイオーネ，
ギリアーノ ベンシ，
ダニエラ リナウド，
ヴェガ マシグナーニ，
ミッチェル バロッチー，
リノ ラップロイ，
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2008508320A publication Critical patent/JP2008508320A/ja
Publication of JP2008508320A5 publication Critical patent/JP2008508320A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2007523880A 2004-07-29 2005-07-29 Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物 Pending JP2008508320A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US59280504P 2004-07-29 2004-07-29
US60983304P 2004-09-13 2004-09-13
US61683304P 2004-10-08 2004-10-08
US63341804P 2004-12-07 2004-12-07
US64006904P 2004-12-30 2004-12-30
US66032105P 2005-03-11 2005-03-11
US67375405P 2005-04-22 2005-04-22
US69300105P 2005-06-21 2005-06-21
US69545305P 2005-07-01 2005-07-01
US69764305P 2005-07-11 2005-07-11
PCT/US2005/027239 WO2006078318A2 (en) 2004-07-29 2005-07-29 Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011161176A Division JP2011206061A (ja) 2004-07-29 2011-07-22 Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物

Publications (2)

Publication Number Publication Date
JP2008508320A true JP2008508320A (ja) 2008-03-21
JP2008508320A5 JP2008508320A5 (https=) 2011-09-08

Family

ID=36692677

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007523880A Pending JP2008508320A (ja) 2004-07-29 2005-07-29 Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
JP2011161176A Pending JP2011206061A (ja) 2004-07-29 2011-07-22 Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011161176A Pending JP2011206061A (ja) 2004-07-29 2011-07-22 Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物

Country Status (5)

Country Link
US (3) US20090317420A1 (https=)
EP (2) EP1784211A4 (https=)
JP (2) JP2008508320A (https=)
CA (1) CA2575548A1 (https=)
WO (1) WO2006078318A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515157A (ja) * 2009-01-12 2012-07-05 ノバルティス アーゲー グラム陽性細菌に対するワクチンにおけるＣｎａ＿Ｂドメイン抗原
JP2013504556A (ja) * 2009-09-10 2013-02-07 ノバルティス アーゲー 気道疾患に対する組み合わせワクチン
JPWO2011040133A1 (ja) * 2009-10-02 2013-02-21 学校法人東京女子医科大学 ヒト血清アミロイドａ３抗体およびその利用
JP2013520487A (ja) * 2010-02-26 2013-06-06 ノバルティス アーゲー 免疫原性タンパク質および組成物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US7534857B2 (en) * 1997-12-19 2009-05-19 Centegen, Inc. Methods and compositions for the treatment and prevention of staphylococcal infections
US20080219976A1 (en) * 1997-12-19 2008-09-11 Naomi Balaban Methods and compositions for treatment and prevention of staphylococcal infections
DK1328543T3 (da) * 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
AU2003260102A1 (en) * 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
JP4875490B2 (ja) 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1784211A4 (en) * 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
WO2006042027A2 (en) * 2004-10-08 2006-04-20 Novartis Vaccines And Diagnostics Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CN101484464A (zh) * 2006-02-17 2009-07-15 诺华有限公司 纯化细菌抗原
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
WO2009027768A2 (en) * 2006-07-26 2009-03-05 Novartis Ag Immunogenic compositions for gram positive bacteria
WO2008108830A2 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
US8660175B2 (en) * 2007-12-10 2014-02-25 Qualcomm Incorporated Selective display of interpolated or extrapolated video units
PL2235046T3 (pl) * 2007-12-21 2012-12-31 Novartis Ag Zmutowane formy streptolizyny O
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
RU2011154363A (ru) * 2009-06-01 2013-07-20 Новартис Аг Комбинации клад rrgb пневмококков
GB201114923D0 (en) * 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
DE102011121069A1 (de) * 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
EP2872535A1 (en) 2012-07-16 2015-05-20 Pfizer Inc. Saccharides and uses thereof
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
EP2897638A1 (en) 2012-09-24 2015-07-29 Montana State University-Bozeman Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
AR101455A1 (es) * 2014-08-05 2016-12-21 Glaxosmithkline Biologicals Sa Molécula portadora
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
TWI598360B (zh) * 2016-12-19 2017-09-11 義守大學 Ｆｓｂｍ重組蛋白及其用途
WO2020085511A1 (ja) * 2018-10-25 2020-04-30 味の素株式会社 タンパク質の分泌生産法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034771A2 (en) * 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
WO2004041157A2 (en) * 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU548947A1 (ru) 1975-09-05 1980-02-05 Всесоюзный Ордена Ленина Институт Экспериментальной Ветеринарии Васхнил Вакцина дл специфической профилактики и трерапии трихофитии лошадей
NO153458C (no) 1978-06-07 1986-03-26 Inst Experimentalnoi Veterinar Fremgangsm¨te for fremstilling av vaksine for profylakse o g behandling av ringorm hos pelsdyr og kaniner for¨rsaket av trichophyton mentagrophytes.
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4454121A (en) * 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2550094B1 (fr) * 1983-08-01 1986-03-21 Anvar Compositions de vaccins conditionnees pour la vaccination de sujets immunitairement non naifs contre un agent pathogene determine et contenant un haptene comportant lui-meme un site antigenique caracteristique dudit agent pathogene ou un oligomere de cet haptene
US5324513A (en) 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5098704A (en) 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
ES2061500T5 (es) 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ227011A (en) 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
US5098827A (en) * 1988-02-26 1992-03-24 The University Of Florida Novel bacterial markers for pathogenic group B streptococci
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
GB8827038D0 (en) 1988-11-18 1988-12-21 Kehoe M Streptolysin o antigens & uses
US5354846A (en) * 1988-11-18 1994-10-11 Michael Kehoe Streptolysin O antigen derivatives, its production and uses
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
RU2121481C1 (ru) 1988-12-16 1998-11-10 Де Стат Дер Недерланден Вертегенвордигд Дор де Министр Ван Велзейн, Волксгезондхейд эн Кюлтюр Модифицированный пневмолизин, рекомбинантная плазмида, способ получения модифицированного пневмолизина, вакцина
GB2233977B (en) 1989-01-04 1993-03-31 Michael Kehoe Cytolytic streptolysin o mutants and uses
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
CA2011896C (en) 1989-04-21 2001-05-08 Mark Werner Ringworm vaccine
DK0398748T3 (da) 1989-05-18 2002-03-18 Chiron Corp NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US6737521B1 (en) * 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5284652A (en) 1990-10-26 1994-02-08 Pier Allan C Dermatophyte vaccine
US5277904A (en) 1990-10-26 1994-01-11 Pier Allan C Broad spectrum dermatophyte vaccine
US5378620A (en) 1991-08-30 1995-01-03 Beckman Instruments, Inc. Streptolysin O derivatives
US5391712A (en) * 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE4240056A1 (de) * 1992-11-28 1994-06-01 Boehringer Mannheim Gmbh Streptolysin O Peptidantigene und Verfahren zur Bestimmung von Streptolysin-Antikörper
DK0613947T3 (da) 1993-02-01 2004-07-05 Beckman Coulter Inc Mitogen faktor, mitogen derfor samt fremgangsmåde til mikrodetektion deraf
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
ATE248918T1 (de) * 1993-06-23 2003-09-15 Beckman Coulter Inc Rekombinante dnase b aus streptococcus pyogenes
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
ATE296877T1 (de) * 1994-10-07 2005-06-15 Univ Rockefeller Enzyme zur spaltung der verankerungsregion von oberflächenproteinen aus gram-positiven bakterien
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6284884B1 (en) * 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6936259B2 (en) * 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6346392B1 (en) 1996-11-27 2002-02-12 Smithkline Beecham Corporation Polynucleotides encoding a novel glutamine transport ATP-binding protein
IES960488A2 (en) 1996-07-03 1997-11-19 Trinity College Dublin Subunit Vaccine for Streptococcus Equi
EP0821070A1 (en) 1996-07-22 1998-01-28 Carelli, Claude Marcel Henri Pit-1 gene polymorphism and trait selection in animals
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
EP0970966B1 (en) 1996-09-04 2008-02-20 Takara Bio Inc. Fungal antigens and process for producing the same
JP4469026B2 (ja) 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
JP2001510989A (ja) 1996-11-01 2001-08-07 スミスクライン・ビーチャム・コーポレイション 新規コーディング配列
US7033765B1 (en) * 1997-02-20 2006-04-25 Toronto Research Chemicals, Inc. Site-specific drug delivery
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
CA2289116A1 (en) * 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US5948413A (en) 1997-07-17 1999-09-07 Board Of Trustees Operating Michigan State University Method and vaccine for treatment of pythiosis insidiosi in humans and lower animals
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
AU751009B2 (en) 1997-09-12 2002-08-08 University Of Tennessee Research Corporation, The Group A streptococcal vaccines
WO1999016882A1 (en) 1997-09-26 1999-04-08 Medimmune, Inc. LMB GENE OF $i(STREPTOCOCCUS AGALACTIAE)
US6406883B1 (en) 1997-09-26 2002-06-18 Luetticken Rudolf Lmb gene of Streptococcus agalactiae
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
BR9813071A (pt) * 1997-10-17 2000-08-15 Nestle Sa Espécie de bactéria láctica
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
AU748950B2 (en) 1997-11-21 2002-06-13 New Zealand Pastoral Agriculture Research Institute Limited Zoocin A immunity factor
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR100735651B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
NZ504894A (en) 1997-12-02 2002-12-20 Powderject Vaccines Inc Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
WO1999035270A1 (en) * 1997-12-31 1999-07-15 Stressgen Biotechnologies Corporation Streptococcal heat shock proteins of the hsp60 family
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
US7041814B1 (en) * 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
ES2540281T3 (es) 1998-02-20 2015-07-09 Id Biomedical Corporation Of Quebec Antígenos de estreptococos del grupo B
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
GB9808327D0 (en) * 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US6660520B2 (en) * 1998-06-05 2003-12-09 Smithkline Beecham Corporation Nrde
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6936252B2 (en) * 1998-07-27 2005-08-30 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
WO2000006736A2 (en) 1998-07-27 2000-02-10 Microbial Technics Limited Nucleic acids and proteins from group b streptococcus
US7098182B2 (en) * 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
BR9914374A (pt) 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7128918B1 (en) * 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
AU4989100A (en) 1999-05-04 2000-11-17 Susan A. Capizzi Method and apparatus for categorizing and retrieving network pages and sites
US6833356B1 (en) * 1999-08-25 2004-12-21 Medimmune, Inc. Pneumococcal protein homologs and fragments for vaccines
CZ20021043A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
US6777547B1 (en) * 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
US6400152B1 (en) * 2000-01-31 2002-06-04 General Electric Company Spiral trajectory calculations for MRI
US20020061569A1 (en) * 2000-03-21 2002-05-23 Robert Haselbeck Identification of essential genes in prokaryotes
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AUPQ801700A0 (en) * 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
JP4718099B2 (ja) * 2000-07-06 2011-07-06 アイディー バイオメディカル コーポレイション ストレプトコッカス・パイオジェンス抗原
PT1320542E (pt) * 2000-08-08 2007-08-06 St Jude Childrens Res Hospital Ácidos nucleicos de estreptococo de grupo b, polipéptidos, composições terapêuticas e vacinas correspondentes
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AU2001294953A1 (en) * 2000-09-29 2002-04-08 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
WO2002057315A2 (en) * 2000-10-10 2002-07-25 University Of Tennessee Research Corporation Streptococcal streptolysin s vaccines
US7160547B2 (en) * 2000-10-10 2007-01-09 University Of Tennessee Research Corporation Streptococcal streptolysin S vaccines
JP2002135314A (ja) 2000-10-26 2002-05-10 Sharp Corp 通信制御方法および通信機器
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
ES2310201T3 (es) 2001-02-13 2009-01-01 Government Of The United States Of America, As Represented By The Secretary Of The Army Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros.
JP2004529906A (ja) 2001-03-19 2004-09-30 イオマイ コーポレイシヨン 経皮的免疫賦活
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
BR0208874A (pt) * 2001-04-13 2004-06-22 Wyeth Corp Proteìnas superficiais de streptococcus pyogenes
US20070128229A1 (en) * 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
FR2824074A1 (fr) * 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
ATE557041T1 (de) * 2001-05-18 2012-05-15 Us Gov Health & Human Serv Peptid-vakzinen gegen streptokokken der gruppe a
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
ATE543906T1 (de) 2002-02-11 2012-02-15 Id Biomedical Corp Antigen von streptococcus aus der b-gruppe
GB2385274B (en) * 2002-02-13 2004-04-14 Ming-Jeng Shue Vaginal suppository delivery device
WO2003087353A2 (en) * 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in membrane biogenesis
US20050181388A1 (en) * 2002-04-02 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
AU2003260102A1 (en) * 2002-08-26 2004-03-11 Chiron Corporation Conserved and specific streptococcal genomes
TW566366U (en) * 2002-09-27 2003-12-11 Wus Tech Co Ltd Labor-saving portable battery equipment for power-driven walking assisted scooter
WO2004035618A2 (en) * 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
SI1601770T1 (sl) 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
EP2275435A3 (en) * 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae antigens I + II
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
JP4875490B2 (ja) * 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
AU2003904237A0 (en) * 2003-08-08 2003-08-21 Garvan Institute Of Medical Research Novel translocation assay
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1721283B1 (en) * 2004-02-06 2022-11-30 Council of Scientific and Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
US20060041961A1 (en) * 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
WO2005108419A1 (en) 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
EP1784211A4 (en) * 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
AU2005335216A1 (en) 2004-10-05 2007-02-15 Wyeth Probe arrays for detecting multiple strains of different species
EP1770171A1 (en) 2005-09-29 2007-04-04 Universität Zu Köln DNA microarray for rapid identification of Candida albicans in blood cultures.
EP2292646A3 (en) 2006-07-07 2011-06-08 Intercell AG Small Streptococcus pyogenes antigens and their use
AT514720B1 (de) 2013-08-30 2016-03-15 Blum Gmbh Julius Stellvorrichtung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034771A2 (en) * 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
WO2004041157A2 (en) * 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6011006146; ＬＡＲＳＳＯＮ，　Ｃ．，　ｅｔ　ａｌ．: 'Ｐｒｏｔｅｃｔｉｏｎ　ａｇａｉｎｓｔ　ｅｘｐｅｒｉｍｅｎｔａｌ　ｉｎｆｅｃｔｉｏｎ　ｗｉｔｈ　ｇｒｏｕｐ　Ｂ　ｓｔｒｅｐｔｏｃｏｃｃｕｓ　ｂｙ　ｉｍｍｕｎｉｚａｔｉｏｎ　ｗｉｔｈ　ａ　ｂｉｖａｌｅｎｔ' Ｖａｃｃｉｎｅ Ｖｏｌ．１７, 1999, ｐ．４５４-４５８ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515157A (ja) * 2009-01-12 2012-07-05 ノバルティス アーゲー グラム陽性細菌に対するワクチンにおけるＣｎａ＿Ｂドメイン抗原
JP2013504556A (ja) * 2009-09-10 2013-02-07 ノバルティス アーゲー 気道疾患に対する組み合わせワクチン
JPWO2011040133A1 (ja) * 2009-10-02 2013-02-21 学校法人東京女子医科大学 ヒト血清アミロイドａ３抗体およびその利用
JP2013520487A (ja) * 2010-02-26 2013-06-06 ノバルティス アーゲー 免疫原性タンパク質および組成物

Also Published As

Publication number Publication date
US20090317420A1 (en) 2009-12-24
EP1784211A2 (en) 2007-05-16
WO2006078318A2 (en) 2006-07-27
US20060165716A1 (en) 2006-07-27
EP2612679A1 (en) 2013-07-10
US8778358B2 (en) 2014-07-15
US20110110982A1 (en) 2011-05-12
WO2006078318A3 (en) 2008-10-30
JP2011206061A (ja) 2011-10-20
EP1784211A4 (en) 2010-06-30
CA2575548A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
US8778358B2 (en) Immunogenic compositions for gram positive bacteria such as Streptococcus agalactiae
JP2008508320A5 (https=)
US20100150943A1 (en) Immunogenic compositions for gram positive bacteria
AU716225B2 (en) Proteinase K resistant surface protein of neisseria meningitidis
US20100074923A1 (en) Purification of bacterial antigens
EP2167531B1 (en) Streptococcus pneumoniae pilus antigens
JP6084631B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
RU2498994C2 (ru) Мутантные формы стрептолизина о
US9102740B2 (en) Cna-B domain antigens in vaccines against gram positive bacteria
JP5653215B2 (ja) Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
JP2010538634A5 (https=)
US8945589B2 (en) Immunogenic compositions for Streptococcus agalactiae
JP6401148B2 (ja) 抗原および抗原の組み合わせ
AU762316B2 (en) Proteinase K resistant surface protein of neisseria meningitidis
AU2013202316A1 (en) Compositions comprising Yersinia pestis antigens

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110704

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110711

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121012

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121029

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20121116